ABION Participates in SITC... Announces Anticancer Efficacy of Next-Generation Platform ‘ABN202’

Abion announced on the 14th that it will participate in the '2024 Society for Immunotherapy of Cancer (SITC)' held in Houston, Texas, USA, from the 6th to the 10th of next month (local time).

SITC is an international academic conference where immuno-oncology researchers from around the world gather. More than 6,000 participants attend annually, and this year marks its 39th edition.

At the conference, Abion will present the excellent anti-cancer effects of its antibody-cytokine fusion protein (ACFP) platform ABN202, which fuses interferon-beta variants to tumor-targeting antibodies, in various solid tumor preclinical models. ACFP is gaining attention as a new therapeutic strategy that overcomes resistance mechanisms of conventional antibody-drug conjugates (ADC).

The company will also disclose preclinical data confirming superior immuno-oncological efficacy in immunosuppressive solid tumor mouse models. Based on this, it explained that there is a high possibility of utilizing it in combination therapy with immune checkpoint inhibitors.

In particular, ACFP shows potential as a safer and more efficient anti-cancer therapeutic by resolving the purification difficulties and systemic toxicity issues associated with conventional interferon-beta. Abion is developing ABN202 as a next-generation platform technology with the potential for indication expansion across various solid tumors.

An Abion representative stated, “ABN202 is receiving significant attention as an innovative therapeutic that can overcome the limitations of existing anti-cancer drugs,” and added, “At this conference, we will discuss commercialization in various ways through partnering with global pharmaceutical companies and stakeholders.”

This content was produced with the assistance of AI translation services.